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Rapidly progressive ACTH-dependent Cushing’s disease masquerading as ectopic
ACTH-producing Cushing’s syndrome: illustrative case
Siyuan Yu, BA,1 Michael Karsy, MD, PhD, MSc,1 Jeffrey Miller, MD,2 Stephanie R. Beldick, MSc,3 Mark T. Curtis, MD,3
Marc Rosen, MD,4 and James J. Evans, MD1,4
Departments of 1Neurological Surgery, 2Endocrinology, 3Pathology, and 4Otolaryngology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

BACKGROUND Cushing’s disease (CD) remains a challenging condition to diagnose and treat. This case study highlights the challenges of diagnosing CD
when faced with discrepant clinical, biochemical, and radiological ﬁndings.
OBSERVATIONS A 62-year-old man presented with rapid evolution of symptoms, including depression, fatigue, and extreme muscle atrophy, which
resulted in the patient being a wheelchair user over the course of a few months. His rapid clinical course in conjunction with hypercortisolemia in the
setting of a pituitary macroadenoma involving the cavernous sinus, two large pulmonary nodules, and urine-free cortisol levels in the thousands
suggested an aggressive ectopic adrenocorticotropic hormone (ACTH) source. After extensive testing ruled out CD from an ectopic source and
because of the patient’s abrupt clinical deterioration, the authors concluded that the source was likely an aggressive pituitary adenoma. Therefore, the
authors performed an endonasal transsphenoidal approach for resection of the pituitary adenoma involving the cavernous sinus, and the patient was
scheduled for radiosurgery to control tumor progression.
LESSONS Although extremely high levels of cortisol and ACTH are associated with ectopic Cushing’s syndrome, they may also indicate an
aggressive form of CD. Suspicion should be maintained for hypercortisolemia from a pituitary source even when faced with discrepant information that
may suggest an ectopic source.
https://thejns.org/doi/abs/10.3171/CASE21151
KEYWORDS Cushing’s disease; Cushing’s syndrome; hypercortisolism; ectopic adrenocorticotropin

Cushing’s syndrome (CS) is characterized by high levels of cortisol in the blood, which may be a result of excessive production of
adrenocorticotropic hormone (ACTH) from the pituitary gland or
ectopic extrapituitary production. Distinguishing excessive production
of cortisol via ACTH-secreting pituitary tumors (ACTH-dependent
Cushing’s disease [CD]) from ectopic tumors that secrete corticotropin-releasing hormone, ACTH (ectopic Cushing’s), or cortisol in an
ACTH-independent manner is important to guide treatment.1 However, the diagnosis of ACTH-dependent CD remains challenging,
especially in the setting of unclear imaging and laboratory ﬁndings.
Our patient presented with myopathy and difﬁculty ambulating
that rapidly worsened in the span of a year. Magnetic resonance imaging
(MRI) revealed a pituitary macroadenoma. However, serological studies,

overall clinical deterioration, and suspicious ﬁndings on computed tomography (CT) scans of the lungs were all suggestive of an ectopic source,
which made the diagnosis challenging.

Illustrative Case
A 62-year-old man with a past medical history of diabetes, hyperlipidemia, and atrial ﬁbrillation presented with rapidly progressive lower
extremity edema, generalized weakness, gait imbalance, and increased
frequency of falls over a few months. Chart review revealed episodes of
hypokalemia with blood glucose level in the range of 300 mg/dL and
multiple admissions for treatment of hyperglycemia, pneumonia, and
metabolic alkalosis. Over a 1-year period, the patient demonstrated
increased fatigue, depressive mood, extreme muscle atrophy, and weight

ABBREVIATIONS ACTH = adrenocorticotropic hormone; CD = Cushing’s disease; CS = Cushing’s syndrome; CT = computed tomography; DST = dexamethasone
suppression test; IHC = immunohistochemistry; MRI = magnetic resonance imaging; UFC = urine-free cortisol.
INCLUDE WHEN CITING Published July 5, 2021; DOI: 10.3171/CASE21151.
SUBMITTED March 13, 2021. ACCEPTED April 26, 2021.
© 2021 The authors, CC BY-NC-ND 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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TABLE 1. Results of 2 mg 48-hour DST and a follow-up 8 mg
48-hour DST
Date

Morning Cortisol
(6.2–19.4 mg/dL)

UFC
(5–64 mg/24 hr)

ACTH
(7.2–63 pg/mL)

2 mg 48-hr DST*
3/2020
3/2020
3/2020
3/2020
4/2020
4/2020
4/2020
4/2020

11.1

135.8
25

17.1
25

162.3
201.9

215
8 mg 48-hr DST*

14.9

163
74

26.2
71.8

1,656

583

*Dexamethasone levels were not available for these tests.

loss of approximatly 60 lb, resulting in the patient becoming a wheelchair
user. The patient did not demonstrate classic cushingoid features.
Blood test results demonstrated a morning cortisol level of 72 mg/
dL (normal range 6.2–19.4 mg/dL); however, subsequent 24-hour
urine-free cortisol (UFC) levels and 1 mg dexamethasone suppression
test (DST) were normal despite two separate measurements. Other
pituitary hormone levels were unremarkable. A 48-hour 2 mg DST
and 8 mg high-dose DST (Table 1) demonstrated elevated ACTH levels and a failure of cortisol suppression. Several additional 24-hour
free cortisol levels were attempted, some in combination with DSTs,
with four measurements showing elevated values. However, UFC levels of 1,656 mg/24 hours (normal level 5–64 mg/24 hours) suggested
an ectopic cortisol source (Table 2). A chest and abdomen CT
revealed two lung cysts (Fig. 1), one of which was biopsied and was
unremarkable for a lung tumor. Additionally, an autoimmune panel
and a muscle biopsy were both nonrevealing. MRI showed a 1.3-cm
pituitary macroadenoma involving the left cavernous sinus (Fig. 1).
Due to the patient’s progressive failure to thrive and lack of deﬁnitive ectopic ACTH source, he underwent an endoscopic resection
of the pituitary macroadenoma. Intraoperatively, gross total resection
of the tumor involving the sella, clivus, and left cavernous sinus was
achieved. Pathology revealed corticotropic pituitary adenoma staining strongly for ACTH and elevated Ki-67 proliferation index of 17%

using immunohistochemistry (IHC) staining (Fig. 2). Postoperative day
1 morning cortisol revealed a level of 30.7 mg/dL, which progressively
decreased to a cortisol level of 5.6 mg/dL at discharge on postoperative day 5. The patient was subsequently placed on steroid replacement. At 3 months follow-up, with the patient on prednisone 7.5 mg
daily, blood test results revealed an ACTH of 43 pg/mL and a morning
cortisol level of 3 mg/dL. He regained 15 lb and was able to ambulate
independently with a cane, and his leg swelling had decreased signiﬁcantly. However, 8 months after surgery, the patient’s cortisol levels
started to climb, which was indictive of recurrence (Table 3). Due to
symptomatic refractory hypercortisolemia, the patient was started on
ketoconazole, and underwent stereotactic radiosurgery. As his cortisol
and ACTH levels continued to be elevated, he underwent bilateral
adrenalectomies. He only then began showing improved cortisol levels, mentation, and functional status.

Discussion
Observations
This report presents the case of a 62-year-old man with rapid clinical
deterioration secondary to hypercortisolemia. In the setting of unclear
localization, including a pituitary macroadenoma concerning for hypercortisolemia of pituitary origin versus pulmonary nodules, UFC levels in
the thousands, and the aggressive nature of the clinical course concerning for hypercortisolemia of ectopic origin, the diagnosis was delayed.
After extensive testing ruling out an ectopic source, the patient ultimately underwent an endonasal transsphenoidal approach for resection
of the pituitary adenoma involving the cavernous sinus that resulted initial in biochemical remission of the patient’s CD. Due to refractory hypercortisolemia, the patient required radiosurgery, ketoconazole treatment,
and eventually bilateral adrenalectomies.
Lessons
CD accounts for 70% to 80% of ACTH-dependent CS, with a
prevalence of 40:1,000,000 and occurrence more common in women,
with a 3:1 female to male ratio.1 The clinical features of CD are highly
variable and may include obesity, abdominal striae, osteoporosis,
delayed wound healing, moon face, and dorsal cervical fat pad, and it
may take as long as 2 to 4 years after initial symptom onset to diagnosis. A prolonged and persistent state of hypercortisolemia increases
a patient’s risk of metabolic syndrome, hyperglycemia, opportunistic
infections, neuropsychiatric disorders, decreased quality of life, and
cardiovascular complications. The mortality rate with CD can be as

TABLE 2. 24-hour UFC test results before surgical treatment
UFC Date*
3/2020
3/2020
3/2020
3/2020
4/2020
4/2020
5/2020
5/2020
*

UFC Per Volume/Total Volume

24-hr UFC (5–64 mg/24 hr)

Test Performed

Outside lab testing
Unable to void
18/2,500 mL
78/2,750 mL
32/2,300 mL
828/2,000 mL
188/2,000 mL
1,410/2,750 mL

27 mg/24 hr
—
25 mg/24 hr
215 mg/24 hr
74 mg/24 hr
1,656 mg/24 hr
376 mg/24 hr
3,878 mg/24 hr

Screening test
Screening test
2 mg 48-hr DST
2 mg 48-hr DST
8 mg 48-hr DST
8 mg 48-hr DST
8 mg 48-hr DST
8 mg 48-hr DST

Patient had a normal creatine level 1.1 (0.76–1.27 mg/dL) in January 2020.

2 | J Neurosurg Case Lessons | Vol 2 | Issue 1 | July 5, 2021

Brought to you by Thomas Jefferson University | Unauthenticated | Downloaded 07/12/21 05:27 PM UTC

FIG. 1. Preoperative and postoperative MRI of an aggressive ACTHsecreting pituitary adenoma. A: Preoperative workup, including CT of
the chest, demonstrated two cystic pulmonary lesions (arrows) that
were biopsied to rule out an ectopic source of ACTH secretion. Preoperative coronal (B) and sagittal (C) postcontrast T1 images demonstrate a hypointense pituitary macroadenoma (arrowheads) with
extension into the left cavernous sinus. D: Postoperative T1 coronal
image with contrast showing removal of the lesion and expected postoperative changes in the sphenoid sinus and cavernous sinus
enhancement.

much as four times higher than that of the general population, with
cardiovascular complications being the leading cause of death.1
The initial workup of CD includes physical examination, evaluation of
exogenous glucocorticoid administration, 24-hour UFC, or three midnight
salivary cortisol tests.2–4 Testing should be performed on separate occasions. Overall sensitivity for these tests ranges from 80% to 98%, with
important caveats for speciﬁc tests.4 Once CD is suspected, conﬁrmatory testing can be performed that involves high-dose DST (8 mg),
measurement of ACTH levels, and brain MRI to localize the pituitary
lesion. CD demonstrates cortisol levels that are 1 to 2 times normal levels as well as ACTH levels that are 3 times normal levels, whereas CS
can have cortisol levels that are 3 to 4 times normal and ACTH levels
that are at or above 10 to 100 times normal. If CS is suspected, wholebody imaging with CT of the chest and abdomen should be conducted
to look for an ectopic source. Additional identiﬁcation of ectopic CS may
involve the use of gallium-68 dotatate positron emission tomography,
which may be helpful in identifying nonpituitary sources of ACTH in
neuroendocrine tumors.5–7 Inferior petrosal sinus sampling may be
attempted to conﬁrm a diagnosis of CD or evaluate for laterality of the
tumor within the sella in cases that are nonlesional on MRI. Guidelines
from the Endocrine Society and the European Society of Endocrinology
help clarify testing but do not completely agree on workup and testing
cutoff values.5–7
Diagnosis of CD may be challenging when patients do not exhibit
concordant clinical signs, biochemical testing, and imaging. One
series looked at biochemical proﬁles of ectopic CS and CD. It found
that ectopic CS had much higher ACTH levels and that ACTH levels

FIG. 2. Histology of pituitary tumor with hematoxylin and eosin and
IHC staining demonstrating an aggressive ACTH-secreting tumor by
elevated Ki-67 index. A: Hematoxylin and eosin stain of the pituitary
adenoma comprised of sheets of cells with eosinophilic cytoplasm and
mildly pleomorphic nuclei (original magniﬁcation 600). Rare mitotic
ﬁgures were present (inset, original magniﬁcation 1,000). B: IHC
stain for chromogranin, a marker of neuroendocrine cells, including
those found in pituitary adenomas, shows strong staining of this pituitary adenoma (original magniﬁcation 600). C: IHC shows strong,
diffuse staining for ACTH in the pituitary adenoma cells, demonstrating
ACTH production by the adenoma cells. This strong pattern of staining
is compatible with this adenoma being an ACTH-secreting pituitary
adenoma (original magniﬁcation 600). D: IHC is negative for thyroid
transcription factor 1 (TTF-1). TTF-1 is a nuclear marker present in
cells of lung, thyroid, and neurohypophyseal origin and in peripheral
systemic neuroendocrine tumors. Given the concerning ﬁndings on
chest CT (see Fig. 1), the absence of staining for TTF-1 supports the
diagnosis of pituitary adenoma rather than a neuroendocrine tumor of
systemic origin (original magniﬁcation 400). E: Positive IHC staining
for Ki-67, a nuclear marker of cell cycle activity. The Ki-67 proliferation
index is 17%, which is elevated and may indicate more aggressive
tumor behavior (original magniﬁcation 400). F: IHC is positive for
nuclear staining of p53, an atypical ﬁnding in pituitary adenomas. The
role of p53 expression in prognostication of pituitary adenomas is
unclear (original magniﬁcation 400).

>200 pg/mL could indicate an ectopic source.8 The variation in cutoff
for CD diagnosis also may result in alteration of test sensitivity/specificity. The Japanese Ministry of Health diagnostic criteria for CD indicates use of low-dose (0.5 mg) DST, with 5.0 mg/dL as the cutoff
value. This combination showed a sensitivity of 97% and a speciﬁcity
of 88% compared to the standard 1 mg DST, which showed a sensitivity of 75% and speciﬁcity of 87% for initial screening test currently
recommended by endocrinology guidelines when studied in the Japanese population.9 Use of circadian variations by measurement of
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TABLE 3. Laboratory values indicting a recurrence of patient’s
CD
Date

Test

Results

11/2020
11/2020
2/2021
2/2021
2/2021
2/2021
3/2021
3/2021
3/2021

ACTH
Morning cortisol
ACTH
Morning cortisol
UFC
ACTH
Morning cortisol
UFC
ACTH

44.6 (7.2–63.3 pg/mL)
3 (6.2–19.4 pg/mL)
159.0 (7.2–63.3 pg/mL)
14.1(6.2–19.4 pg/mL)
323 (5–64 mg/24 hr)*
176 (7.2–63.3 pg/mL)
83.2(6.2–19.4 pg/mL)
No result
228.0 (7.2–63.3 pg/mL)

*02/2021 creatinine level 1.5 (0.76–1.27 mg/dL).

cortisol and ACTH pulsatility without concurrent use of dexamethasone
suppression testing also showed high sensitivity and speciﬁcity for distinguishing CD from a pseudo-Cushing’s state.10 Separating CD from
an ectopic source seems straightforward but can be difﬁcult from a biochemical perspective. High-dose DST gives a variable sensitivity and
speciﬁcity of 60% to 100% and 65% to 100% for CD, respectively. A
reported series of ectopic tumors revealed that when a cutoff of 60%
suppression was used for high-dose DST, the sensitivity for diagnosing
ectopic cortisol sources increased from 91% to 97%.11 Caveats include
mention that ectopic tumors are appropriately suppressed by high-dose
DST 5% to 25% of the time, and up to 20% of patients with CD fail to
suppress with high-dose DST.12 Some authors have argued that
high-dose DST cannot accurately distinguish between well-differentiated
systemic tumors and pituitary adenomas.13
Use of alternative tests in addition to standard tests may be helpful
in guiding CD diagnosis but remains limited. One alternative test
includes use of desmopressin (DDAVP). DDAVP is structurally similarly
to vasopressin, which acts on the kidneys to mediate water reabsorption. It also stimulates release of ACTH and cortisol in a proportion of
patients with ACTH-mediated CS while having minimal effect on
healthy people. One study showed 90.8% sensitivity and 94.6% specificity in diagnosing CD in a population of patients suspected of having
CS.14 Additional application of DDAVP response may be used to monitor recurrence in CD. Loss of DDAVP response after surgery is correlated with favorable outcome whereas return of response corresponds
with recurrence.15
Our case involving CD is extremely unusual given the high cortisol
and ACTH levels and the rapid deterioration of the patient’s clinical
symptoms that are highly suggestive of CD from an ectopic source.
IHC revealed positive staining for ACTH pituitary adenoma with an elevated Ki-67 proliferation index of 17%. Resolution of cortisol and
ACTH levels, along with clinical improvement, conﬁrmed the pituitary
source of the disease. It is unclear whether the high Ki-67 index in this
patient may have resulted in a more aggressively growing tumor, which
could have impacted the high cortisol and ACTH levels as well as the
rapid clinical progression of symptoms. Our case serves as a reminder
that the workup and diagnosis of CD may be challenging given the
incongruous biochemical, clinical, and radiological information. Although
our dedicated pituitary team has more than 20 years of experience in
managing patients with CD, the diagnosis in our patient was ultimately

made only after extensive testing ruled out ectopic CS, which resulted
in delayed surgical management and worsening of our patient’s clinical
symptoms. The case further suggests that a high level of suspicion
should be maintained for hypercortisolemia from a pituitary source
even when faced with unclear clinical information that might suggest
an ectopic source. Improved diagnostic criteria and interdisciplinary
care among neurosurgery and endocrinology can help with proper
patient selection and earlier treatment.
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